Inflammatory mechanisms of hyperuricemia and strategies for drug development
LUO Yu
YIN Xiangnan
XU Qiang
WANG Tao
Abstract：Hyperuricemia(HUA)is an independent risk factor for gout,metabolic syndrome,and cardiovascular disea-ses,with a global adult prevalence rate of 16％～20％.Recent studies have revealed that the inflammatory plays a central role in the pathological process of HUA.It triggers the release of IL-1β by activating the NLRP3 inflammasome,initiating the in-nate immune response;Dendritic cells(DCs)further mediate the Th17/Treg imbalance,amplifying the adaptive immune in-flammatory cascade.Meanwhile,some inflammatory cytokines form a vicious cycle of"uric acid inflammation"by upregulat-ing xanthine oxidase activity and inhibiting uric acid excretion,exacerbating organ damage.Although traditional urate-low-ering drugs can control serum uric acid levels,they cannot block the inflammatory pathway.Targeted NLRP3 pathway inhibi-tors,drugs with dual anti-inflammatory/uricosuric functions(such as modified NSAIDs),and metabolic regulation strategies provide new directions for treatment.Analyzing the inflammation-metabolism interaction network is key to developing precise therapies for HUA.
Keywords：HyperuricemiaInflammationInnate immune cellsTh17/Treg and inflammatory cytokines
Publication Date：2025-11-30
Online Publishing Date：2025-12-24(First online date of this platform, not the publication date of the document)
Pages：10( 1119-1127,1144 )